usfda: Aurobindo Pharma receives warning from SEBI for non-disclosures related to USFDA audit
rugmaker on Monday told stock exchanges that it has received a "warning letter" from the Securities and Exchange Board of India (SEBI) alleging lack of sufficient disclosures involving the audit by the USFDA at its Unit-I. an API…